Home » Stocks » ETTX

Entasis Therapeutics Holdings Inc. (ETTX)

Stock Price: $3.00 USD 0.05 (1.69%)
Updated Jan 20, 2021 3:12 PM EST - Market open
Market Cap 104.65M
Revenue (ttm) n/a
Net Income (ttm) -53.84M
Shares Out 29.96M
EPS (ttm) -2.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $3.00
Previous Close $2.95
Change ($) 0.05
Change (%) 1.69%
Day's Open 2.97
Day's Range 2.77 - 3.10
Day's Volume 570,822
52-Week Range 1.61 - 5.56

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of nove...

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of nove...

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of nove...

GlobeNewsWire - 3 months ago

WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of nove...

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of n...

GlobeNewsWire - 4 months ago

Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial

GlobeNewsWire - 5 months ago

WALTHAM, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of no...

Zacks Investment Research - 6 months ago

Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

GlobeNewsWire - 6 months ago

WALTHAM, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of no...

GlobeNewsWire - 7 months ago

WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of no...

GlobeNewsWire - 7 months ago

WALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and devel...

GuruFocus - 8 months ago

Wall Street sell-side analysts are positive about Ekso Bionics Holdings Inc (NASDAQ:EKSO) and Entasis Therapeutics Holdings Inc (NASDAQ:ETTX), even though their holdings have lost more than 59...

Other stocks mentioned: EKSO
GlobeNewsWire - 8 months ago

WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and deve...

GlobeNewsWire - 1 year ago

CEO Dr. Manos Perros participated in Industry Panel today CEO Dr. Manos Perros participated in Industry Panel today

GlobeNewsWire - 1 year ago

GENEVA and WALTHAM, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organization developing new treatments for ...

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of n...

Zacks Investment Research - 1 year ago

Entasis Therapeutics Holdings Inc. (ETTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

About ETTX

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II... [Read more...]

Industry
Biotechnology
IPO Date
Sep 26, 2018
CEO
Dr. Manoussos Perros
Employees
48
Stock Exchange
NASDAQ
Ticker Symbol
ETTX
Full Company Profile

Financial Performance

In 2019, ETTX's revenue was $7.00 million, an increase of 40.00% compared to the previous year's $5.00 million. Losses were -$43.85 million, 4.17% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ETTX stock is "Buy." The 12-month stock price forecast is 6.50, which is an increase of 116.67% from the latest price.

Price Target
$6.50
(116.67% upside)
Analyst Consensus: Buy